BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 17538890)

  • 1. Predictors of pneumococcal conjugate vaccine immunogenicity among infants and toddlers in an American Indian PnCRM7 efficacy trial.
    O'Brien KL; Moisi J; Moulton LH; Madore D; Eick A; Reid R; Weatherholtz R; Millar E; Hu D; Hackell J; Kohberger R; Siber G; Santosham M
    J Infect Dis; 2007 Jul; 196(1):104-14. PubMed ID: 17538890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
    Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
    Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of the American Academy of Pediatrics--recommended sequential pneumococcal conjugate and polysaccharide vaccine schedule in pediatric solid organ transplant recipients.
    Lin PL; Michaels MG; Green M; Mazariegos GV; Webber SA; Lawrence KS; Iurlano K; Greenberg DP
    Pediatrics; 2005 Jul; 116(1):160-7. PubMed ID: 15995047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, safety, and predictors of response after a pneumococcal conjugate and pneumococcal polysaccharide vaccine series in human immunodeficiency virus-infected children receiving highly active antiretroviral therapy.
    Abzug MJ; Pelton SI; Song LY; Fenton T; Levin MJ; Nachman SA; Borkowsky W; Rosenblatt HM; Marcinak JF; Dieudonne A; Abrams EJ; Pathak I;
    Pediatr Infect Dis J; 2006 Oct; 25(10):920-9. PubMed ID: 17006288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticapsular serum antibody concentration and protection against pneumococcal colonization among children vaccinated with 7-valent pneumococcal conjugate vaccine.
    Millar EV; O'Brien KL; Bronsdon MA; Madore D; Hackell JG; Reid R; Santosham M
    Clin Infect Dis; 2007 May; 44(9):1173-9. PubMed ID: 17407035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and boosting after a reduced number of doses of a pneumococcal conjugate vaccine in infants and toddlers.
    Goldblatt D; Southern J; Ashton L; Richmond P; Burbidge P; Tasevska J; Crowley-Luke A; Andrews N; Morris R; Borrow R; Cartwright K; Miller E
    Pediatr Infect Dis J; 2006 Apr; 25(4):312-9. PubMed ID: 16567982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of community-wide conjugate pneumococcal vaccine use in infancy on nasopharyngeal carriage through 3 years of age: a cross-sectional study in a high-risk population.
    Millar EV; O'Brien KL; Watt JP; Bronsdon MA; Dallas J; Whitney CG; Reid R; Santosham M
    Clin Infect Dis; 2006 Jul; 43(1):8-15. PubMed ID: 16758412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine.
    Bryant KA; Block SL; Baker SA; Gruber WC; Scott DA;
    Pediatrics; 2010 May; 125(5):866-75. PubMed ID: 20435707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
    Shinefield HR; Black S; Ray P; Chang I; Lewis N; Fireman B; Hackell J; Paradiso PR; Siber G; Kohberger R; Madore DV; Malinowski FJ; Kimura A; Le C; Landaw I; Aguilar J; Hansen J
    Pediatr Infect Dis J; 1999 Sep; 18(9):757-63. PubMed ID: 10493334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years.
    Miernyk KM; Parkinson AJ; Rudolph KM; Petersen KM; Bulkow LR; Greenberg DP; Ward JI; Brenneman G; Reid R; Santosham M
    Clin Infect Dis; 2000 Jul; 31(1):34-41. PubMed ID: 10913393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity for 16 serotypes of a unique schedule of pneumococcal vaccines in a high-risk population.
    Leach AJ; Morris PS; Mackenzie G; McDonnell J; Balloch A; Carapetis J; Tang M
    Vaccine; 2008 Jul; 26(31):3885-91. PubMed ID: 18562052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM197 in United States infants.
    Rennels MB; Edwards KM; Keyserling HL; Reisinger KS; Hogerman DA; Madore DV; Chang I; Paradiso PR; Malinoski FJ; Kimura A
    Pediatrics; 1998 Apr; 101(4 Pt 1):604-11. PubMed ID: 9521941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain.
    Diez-Domingo J; Gurtman A; Bernaola E; Gimenez-Sanchez F; Martinon-Torres F; Pineda-Solas V; Delgado A; Infante-Marquez P; Liang JZ; Giardina PC; Gruber WC; Emini EA; Scott DA
    Vaccine; 2013 Nov; 31(46):5486-94. PubMed ID: 24004465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of an alternative reduced-dose infant schedule and a second year catch-up schedule with 7-valent pneumococcal conjugate vaccine on pneumococcal carriage: a randomized controlled trial.
    Dagan R; Givon-Lavi N; Porat N; Greenberg D
    Vaccine; 2012 Jul; 30(34):5132-40. PubMed ID: 22683519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants.
    Choo S; Zhang Q; Seymour L; Akhtar S; Finn A
    J Infect Dis; 2000 Oct; 182(4):1260-3. PubMed ID: 10979930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater antibody responses to an eleven valent mixed carrier diphtheria- or tetanus-conjugated pneumococcal vaccine in Filipino than in Finnish or Israeli infants.
    Puumalainen T; Dagan R; Wuorimaa T; Zeta-Capeding R; Lucero M; Ollgren J; Käyhty H; Nohynek H
    Pediatr Infect Dis J; 2003 Feb; 22(2):141-9. PubMed ID: 12586978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.